RUO onlyMetabolicLongevity

5-Amino-1MQ

5-Amino-1-methylquinolinium / NNMT inhibitor / SBI-477

A small molecule NNMT (Nicotinamide N-methyltransferase) inhibitor — not technically a peptide, but a research compound widely carried by peptide vendors with significant interest in longevity and metabolic research communities. NNMT is an enzyme that consumes NAD+ precursors and promotes fat storage. Inhibiting it raises NAD+ levels and shifts metabolism toward fat burning. Animal data is promising. Human research is limited.

Note: 5-Amino-1MQ is a small molecule NNMT inhibitor, not technically a peptide. We include it because it is carried by most research peptide vendors and researched by the same longevity and metabolic health community.

Evidence

Limited human data

Routes

oral, injectable

Available since

Available through RUO vendors, most commonly in oral capsule formulations.

Mechanism of action

Inhibits NNMT — an enzyme that methylates nicotinamide using SAM (S-adenosyl methionine) as a methyl donor. NNMT activity depletes both NAD+ precursors and the methyl pool. By inhibiting NNMT: NAD+ levels rise (similar effect to NMN/NR supplementation), SAM availability increases supporting methylation reactions, adipocyte differentiation is reduced and existing fat cells shift toward leaner phenotype. Works through a fundamentally different mechanism from GLP-1 compounds — it does not suppress appetite but changes cellular energy metabolism directly.

Effects in the body

5-Amino-1MQ animal data is genuinely interesting for longevity and metabolic researchers. Studies in mice show fat mass reduction without caloric restriction, increased metabolic rate, improved insulin sensitivity, and NAD+ elevation comparable to NMN supplementation. The mechanistic case for human translation is credible. Published human clinical trials are absent as of 2026.

Pros & cons (from the literature)

Pros

NNMT inhibition raises NAD+ through a different mechanism than NMN or NR supplementation
Fat mass reduction in animal models without caloric restriction
Oral administration available — no injection required
Synergistic with NAD+ precursors through complementary mechanisms
Small molecule stability — does not require cold chain storage like many peptides
Dual metabolic and longevity research application

Cautions

Not technically a peptide — small molecule NNMT inhibitor
No published human clinical trials as of 2026
Animal-to-human translation unvalidated
NNMT has roles beyond fat metabolism — systemic inhibition effects not fully characterized
Long-term safety profile unknown
Research community enthusiasm may be running ahead of the published evidence

Protocol summary (from published research)

Animal studies used oral administration at 200mg/kg. Human research protocols not established. Oral capsule formulations most common in vendor catalogs.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Research Use Only. Not FDA approved. A small molecule NNMT inhibitor, not a peptide. No human clinical trials completed. Oral or injectable research compound.

Evidence base

Kraus et al. fat mass reduction mouse study published. NAD+ elevation animal data documented. No human RCTs. Mechanistically credible but preclinical only.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.